Atrium Therapeutics Reports Third Quarter 2026 Financial Results
Atrium Therapeutics Q3 EPS $(0.25) Beats $(1.37) Estimate, Sales $15.321M Beat $666.667K Estimate
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
Atrium Therapeutics To Present New Nonclinical Data On ATR 1072 For Potential Treatment Of PRKAG2 At The American Heart Association Scientific Sessions On November 6; ATR 1072 Impacted Key Characteristics Of PRKAG2, Including Accumulation Of Cardiac Glycogen And Cardiac Hypertrophy
HC Wainwright & Co. Maintains Buy on Atrium Therapeutics, Lowers Price Target to $20
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
Atrium Therapeutics Doses First Patient In Its Phase 1/2 Corventis Clinical Trial Evaluating ATR 1072 For Potential Treatment Of PRKAG2 Syndrome; Expects Initial Proof-Of-Concept Data In H2 2027
Roth Capital Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $15
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
Shareholder Yakira Capital Urges Atrium Therapeutics To Explore Strategic Sale Or Partnerships, Citing 44% Stock Decline, $50M Dilutive Financing
Atrium: Initiating "Hold" ATR 1072 IND Clearance And 2nd Half 2027 PRKAG2 Syndrome Data
Atrium Therapeutics Announces $50 Million Private Placement
Atrium Therapeutics Announces $50M Private Placement Of 5,170,384 Shares And Pre-Funded Warrants To Purchase Up To 1,134,930 Shares At ~$7.93/Unit
Atrium Therapeutics to Participate in Upcoming Investor Conferences
HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target
Atrium Therapeutics Q2 EPS $(1.18) Misses $(1.01) Estimate, Sales $3.004M Beat $2.000M Estimate
HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.